Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Entrada Therapeutics (TRDA) Accumulated Depreciation & Amortization (2020 - 2026)

Entrada Therapeutics has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $9.9 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 5.41% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, up 5.41%, while the annual FY2025 figure was $9.9 million, 5.41% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $9.9 million at Entrada Therapeutics, down from $10.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $11.3 million in Q2 2025 and troughed at $1.4 million in Q4 2021.
  • A 5-year average of $6.2 million and a median of $5.9 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 133.12% in 2022 and later rose 5.41% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.4 million in 2021, then skyrocketed by 133.12% to $3.3 million in 2022, then soared by 79.43% to $5.9 million in 2023, then surged by 59.11% to $9.4 million in 2024, then rose by 5.41% to $9.9 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for TRDA at $9.9 million in Q4 2025, $10.2 million in Q3 2025, and $11.3 million in Q2 2025.